Table 2.
CDC activity of anti-EGFR antibodies against EGFR tumor cell lines.
| MDA-MB-468 |
HCC827 |
A431 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Antibody | EC50 (nM) | % Cytotoxicity at maximal antibody concentration | Pa | EC50 (nM) | % Cytotoxicity at maximal antibody concentration | P | EC50 (nM) | % Cytotoxicity at maximal antibody concentration | P |
| QD6 IgG | NA | 30.8 | NA | 14.5 | NA | 12.8 | |||
| Tdev4 IgG | 9.0 | 46.7 | 0.0174 | 7.5 | 32.1 | 0.0002 | 0.6 | 22.7 | NS |
| GLH4 IgG | 15.2 | 89.5 | <0.0001 | 21.2 | 87.6 | <0.0001 | NA | 87.4 | <0.0001 |
| QD6/NMGC DuetMab | 4.9 | 81.6 | <0.0001 | 7.5 | 78.9 | <0.0001 | 3.1 | 89.7 | <0.0001 |
| GA201 IgG | NA | 17.4 | NA | 15.5 | NA | 8.0 | |||
| GA201/NMGC DuetMab | 10.7 | 86.5 | <0.0001 | 11.1 | 74.9 | <0.0001 | 7.0 | 48.4 | 0.0008 |
| Cetuximab IgG | NA | 6.2 | NA | 39.0 | NA | 15.6 | |||
| Cetuximab/NMGC DuetMab | 2.7 | 54.0 | 0.0005 | 7.1 | 69.7 | 0.0043 | 3.4 | 59.1 | 0.0006 |
aP: One-way analysis of variance and unpaired t test were used to determine statistically significant CDC at maximal antibody concentration tested. Statistical significance was accepted for P < 0.05 at 95% confidence interval.
NA = not available; NS = not significant.